阿托伐他汀治疗重度Ⅲ型及混合型血脂异常的长期疗效与安全性。

Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia.

作者信息

van Dam M, Zwart M, de Beer F, Smelt A H M, Prins M H, Trip M D, Havekes L M, Lansberg P J, Kastelein J J P

机构信息

Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, 1105 AZ Amsterdam, Netherlands.

出版信息

Heart. 2002 Sep;88(3):234-8. doi: 10.1136/heart.88.3.234.

DOI:10.1136/heart.88.3.234

PMID:12181212

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1767327/

Abstract

BACKGROUND

Fibric acid derivatives and HMG-CoA reductase inhibitors are effective in combination for treating patients with familial dysbetalipoproteinaemia and severe combined dyslipidaemia, but combination therapy affects compliance and increases the risk of side effects.

AIM

To evaluate the efficacy and safety of monotherapy with atorvastatin, an HMG-CoA reductase inhibitor with superior efficacy in lowering low density lipoprotein cholesterol and triglyceride concentrations, in patients with dysbetalipoproteinaemia and severe combined dyslipidaemia.

METHODS

Atorvastatin was tested as single drug treatment in 36 patients with familial dysbetalipoproteinaemia and 23 patients with severe combined dyslipidaemia.

RESULTS

After 40 weeks of 40 mg atorvastatin treatment decreases in total cholesterol, triglycerides, and apolipoprotein B of 40%, 43%, and 41%, respectively, were observed in the combined dyslipidaemia group, and of 46%, 40%, and 43% in the dysbetalipoproteinaemic patients. Target concentrations of total cholesterol (< 5 mmol/l) were reached by 63% of the patients, and target concentrations of triglycerides (< 3.0 mmol/l) by 66%. Treatment with atorvastatin was well tolerated and no serious side effects were reported.

CONCLUSIONS

Atorvastatin is very effective as monotherapy in the treatment of familial dysbetalipoproteinaemia and severe combined dyslipidaemia.

摘要

背景

纤维酸衍生物和HMG-CoA还原酶抑制剂联合使用对治疗家族性异常β脂蛋白血症和严重混合型血脂异常患者有效，但联合治疗会影响依从性并增加副作用风险。

目的

评估阿托伐他汀单药治疗对异常β脂蛋白血症和严重混合型血脂异常患者的疗效和安全性，阿托伐他汀是一种在降低低密度脂蛋白胆固醇和甘油三酯浓度方面具有卓越疗效的HMG-CoA还原酶抑制剂。

方法

对36例家族性异常β脂蛋白血症患者和23例严重混合型血脂异常患者进行阿托伐他汀单药治疗试验。

结果

在混合型血脂异常组中，40毫克阿托伐他汀治疗40周后，总胆固醇、甘油三酯和载脂蛋白B分别降低了40%、43%和41%；在异常β脂蛋白血症患者中分别降低了46%、40%和43%。63%的患者达到了总胆固醇的目标浓度（<5毫摩尔/升），66%的患者达到了甘油三酯的目标浓度（<3.0毫摩尔/升）。阿托伐他汀治疗耐受性良好，未报告严重副作用。